CUAMC
SABS icon

China Universal Asset Management Company’s SAB Biotherapeutics SABS Stock Holding History

China Universal Asset Management Company’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-40
Closed – – 454
2022
Q3 		$0 Buy
+40
New +$397 ﹤0.01% 456

Other funds holding SABS

FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
V
Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
IFAM
Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

China Universal Asset Management Company's SABS Position: Q4 2022 in Review

China Universal Asset Management Company sold out of SAB Biotherapeutics (SABS) in Q4 2022, closing a stake of 40 shares.

China Universal Asset Management Company first reported a position in SABS in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 38 funds tracked by Wall St. Rank hold SABS as of Q4 2022.

  • China Universal Asset Management Company reported no remaining SAB Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • China Universal Asset Management Company sold 40 SAB Biotherapeutics shares in Q4 2022.
  • China Universal Asset Management Company first reported a position in SAB Biotherapeutics in Q3 2022 and held it in 1 quarter.
  • China Universal Asset Management Company's SAB Biotherapeutics position peaked at $0 in Q3 2022.
  • 38 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2022.

Based on China Universal Asset Management Company's 13F filing for Q4 2022, filed 31 Jan 2023.